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We have previously shown that treatment of human cytomegalovirus-infected cells with the cyclin-dependent
kinase (cdk) inhibitor roscovitine has significant effects on several stages of the virus life cycle depending on
the time of addition (V. Sanchez, A. K. McElroy, J. Yen, S. Tamrakar, C. L. Clark, R. A. Schwartz, and D. H.
Spector, J. Virol. 78:11219–11232, 2004; V. Sanchez and D. Spector, J. Virol. 80:5886–5896, 2006). In this
report, we add to these findings by demonstrating alterations in the phosphorylation and localization of pp65
(UL83) in cells treated with roscovitine. We observed that inhibition of cdk activity causes the retention of pp65
within the nucleus at late times postinfection. At the same time, we observed a change in the phosphorylation
pattern of the protein. Interestingly, mutation of potential cdk phosphorylation sites did not affect the ability
of pp65 to localize to the nucleus or to relocalize to the cytoplasm late in infection. However, we found that the
cytoplasmic accumulation of pp65 late in infection was sensitive to the Crm1 inhibitor leptomycin B.
Human cytomegalovirus (HCMV), the largest member of
the herpesvirus family, is a ubiquitous pathogen that remains
the leading viral cause of birth defects (13). Like that of other
herpesviruses, HCMV gene expression is temporally regulated
(10). The immediate-early (IE) class of genes is expressed
shortly after infection, and their expression requires no de
novo protein synthesis. The IE genes encode proteins impor-
tant for the modulation of the apoptotic response to infection
(for a review, see reference 4) and for the expression of the
early (E) genes, which are necessary for viral DNA replication.
The early proteins have also been implicated in the altered
expression of key cell cycle proteins during infection (8, 19).
Viral DNA synthesis is a prerequisite for the synthesis of the
late RNAs, which encode structural components of the virion
and proteins that function in virion maturation (10).
Numerous studies have examined the assembly pathways for
the herpesviruses (for a review, see reference 9). The current
model describes the encapsidation of the viral DNA in the
nucleus, followed by egress of subviral particles through the
nuclear envelope. This process is thought to occur through an
initial envelopment at the inner nuclear membrane and a sub-
sequent de-envelopment step at the outer nuclear membrane.
The immature virions are then transported to the final site of
envelopment in the cytoplasm. The acquisition of the tegument
proteins likely occurs in both the nucleus and the cytoplasm,
since the steady-state localization of some HCMV tegument
proteins is restricted during infection (1, 7, 22, 26). The distri-
bution of other tegument proteins is temporally regulated (5,
11, 18, 27). The best-studied example of this temporal regula-
tion of virion proteins is the biphasic localization of the abun-
dant tegument protein pp65. As part of the incoming virion,
pp65 is targeted to the nucleus immediately after infection
(24). Expression of UL83 is an early-late event, and the newly
synthesized pp65 is observed in the nucleus until some time
after 48 h postinfection (p.i.). Thereafter, pp65 accumulates in
the cytoplasm, and the nucleus becomes devoid of the protein
(18). The pp65 nuclear localization signals (NLS) have been
mapped and are contained in the carboxy-terminal one-third of
the protein (6, 24); however, the underlying cause of the relo-
calization of pp65 to the cytoplasm late in infection has not yet
been elucidated.
A recent report has described the aggregation of pp65 in
cells infected with an HCMV viral kinase UL97 mutant (15).
The aggregation of pp65 in large nuclear and cytoplasmic
structures was also detected upon treatment of cells with
maribavir, a UL97 inhibitor. Interestingly, redistribution of
pp65 to the cytoplasm late in infection was still observed in the
absence of UL97 activity. A role for UL97 in the regulation of
pp65 self-aggregation was supported by experiments in which
transient coexpression of UL97 and an enhanced green fluo-
rescent protein (EGFP)-pp65 fusion protein resulted a diffuse
pattern of pp65 expression in the nucleus, as opposed to a
punctate nuclear pattern in the absence of UL97. Based on
these and other data, the authors concluded that pp65 was a
likely substrate for UL97 kinase activity. However, the pp65
sequence contains consensus phosphorylation sites for numer-
ous cellular kinases, including the cyclin-dependent kinases
(cdk). In fact, a putative phosphorylation site overlaps the
bipartite NLS at the carboxy terminus of pp65 (24). Thus, it is
possible that phosphorylation of this site could modulate rec-
ognition of the NLS by the nuclear import machinery late in
infection, resulting in cytoplasmic accumulation of pp65.
Our lab has previously reported the inhibition of HCMV
infection by treatment of cells with the cdk inhibitor roscovi-
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tine (20, 21). We observed that the level of inhibition was
dependent on the time at which the drug was first added to the
infected cultures. If roscovitine was added from the onset of
infection, the processing of IE transcripts was altered, expres-
sion of specific E proteins and viral DNA replication were
inhibited, and the titer was reduced 2 to 3 log units (20). The
effects on viral gene expression and DNA replication were not
as significant if addition of the drug was delayed until 24 h p.i.
(21). In this case, we observed a lag in the expression of several
viral proteins, a two- to threefold reduction in replication, and
a 1- to 2-log-unit drop in titers. The steady-state levels of pp65
were not significantly affected. In contrast, the expression of
the IE2-86 protein was markedly reduced. We also noted that
ppUL69 accumulated in a hyperphosphorylated form. The re-
duced titer produced upon drug treatment was attributed to a
reduction in the production of extracellular virus particles,
based on a reduced amount of viral DNA in the supernatant.
Our data thus suggested that cdk activity was required for the
maturation and/or release of infectious virus.
We have extended these preliminary studies on the effect of
cdk inhibition on late events in HCMV infection. The transi-
tion of pp65 from the nucleus to the cytoplasm was delayed in
roscovitine-treated cells. These changes in localization may be
related to alterations in the phosphorylation pattern of pp65 in
the presence of the drug; however, the results of our muta-
tional analyses of cdk phosphorylation sites in the protein
suggest that these sites do not regulate pp65 localization. In
addition, we report that in infected cells the export of pp65
from the nucleus is dependent on Crm1, and our data suggest
that pp65 is a nucleocytoplasmic shuttling protein. Further-
more, our results indicate that late in infection, the equilibrium
between nuclear import and export changes, resulting in accu-
mulation of pp65 in the cytoplasm.
MATERIALS AND METHODS
Cell culture and virus. Human foreskin fibroblasts (HFF) were maintained in
minimal essential medium-Earle’s medium supplemented with 10% fetal bovine
serum, penicillin, streptomycin, amphotericin, and glutamine, as described pre-
viously (19). Cells were synchronized in G0 by allowing them to grow to conflu-
ence and to arrest for 3 additional days before trypsinization and replating at a
lower density. Cells were infected at a multiplicity of infection (MOI) of 5 with
the Towne strain of HCMV at the time of release from confluence. Mock-
infected cells were incubated with an equal volume of conditioned medium. Cells
were plated at a density of 8  105 per 10-cm-diameter dish containing glass
coverslips and were maintained in 8 ml of complete medium. At 24 h p.i.,
roscovitine or dimethyl sulfoxide (DMSO) was added as indicated. At 24 h p.i.,
roscovitine (EMD Biosciences or Sigma) was added to a final concentration of 20
M. Media and chemicals were replenished every 24 h thereafter.
In separate experiments, the localization phenotypes of wild-type or mutant
forms of pp65 were determined by infection of cells transfected with plasmids
encoding the constructs of interest. Mutations at threonine 66 (T66A) or threo-
nine 555 (T555A) were made in plasmid pEGFP-pp65 (Clontech Laboratories)
using the QuikChange kit from Stratagene according to the manufacturer’s
instructions. The sequences for the mutagenesis primers are as follows: 5-GT
ACACGCCCGACTCGGCGCCATGCCACCG-3 and its complement for the
T66A mutation; 5-GCTTTTTGGGCGCCGAGGCGATGCATGG-3 and its
complement for the T555A mutation. The generation of the desired mutations
was confirmed by sequencing. The EGFP-coding sequences were removed from
pp65 by subcloning the pp65-coding sequence into pcDNA3. HFF were electro-
porated with 10 g of plasmid DNA and plated onto glass coverslips. For initial
experiments, cells transfected with pEGFP-pp65, pEGFP-pp65 T66A, or
pEGFP-pp65 T55A were infected 1 day postelectroporation at an MOI of ap-
proximately 5 with the Towne strain of HCMV. Cultures were fixed in 2%
formaldehyde in phosphate-buffered saline (PBS) 72 h p.i. For later experiments,
transfected cells were infected with HCMV Towne at an MOI of approximately
3 at 6 h posttransfection. Cultures were fixed as described above at 72 to 96 h p.i.
Similar experiments were performed using pcDNA3-pp65, pcDNA3-pp65 T66A,
or pcDNA3-pp65 T555A for transfection, followed by infection with the HCMV
Ad169 pp65-deletion mutant RV (25), a kind gift from Bodo Plachter, at an MOI
of approximately 3. Cells were fixed 96 h p.i. and stained with monoclonal
antibody 65-8.
Immunofluorescence. Confluence-synchronized cells were seeded on glass
coverslips, infected, and treated with roscovitine at 24 h p.i., as described above.
To test the reversibility of cdk inhibition by roscovitine, the drug was removed at
48 h p.i., and cells were fed with complete medium without the drug. In some
experiments, 20 M roscovitine, 1.8 M leptomycin B (LMB) (EMD Bio-
sciences), and/or 100 g/ml cycloheximide was added starting at 72 h p.i. At 72,
73, 75, and 96 h p.i., coverslips were fixed in 2% paraformaldehyde in PBS for 15
min at room temperature. Cells were stained with monoclonal antibodies to pp65
(28-19 and 65-8) and Hoechst stain as previously described (17). For quantifi-
cation of nuclear staining, cells were stained with monoclonal antibody 28-19.
Phosphopeptide mapping of pp65. G0-synchronized HFF were either infected
at the time of release from confluence with HCMV Towne at an MOI of 5 or
mock infected. At 24 h p.i., roscovitine or DMSO was added. Media and treat-
ments were replenished at 48 h p.i. At 66 h p.i., cells were washed and starved in
phosphate-free minimal essential medium (Caisson Laboratories) supplemented
with antibiotics and dialyzed fetal bovine serum, and containing roscovitine or
DMSO, for 1 to 2 h. The medium on each plate was then replaced with 5 ml of
fresh, warm supplemented phosphate-free medium that contained 5 mCi of 32Pi
(MP Biomedicals). After labeling for 1 to 2 h, cells were washed with ice-cold
Tris-buffered saline and harvested by scraping in NETN buffer (20 mM Tris [pH
8.0], 100 mM NaCl, 1 mm EDTA, 0.5% NP-40) containing protease and phos-
phatase inhibitors (1 mM sodium metabisulfite, 10 mM sodium pyrophosphate,
50 mM sodium fluoride, 1 mM sodium orthovanadate, 4 mM phenylmethylsul-
fonyl fluoride, 50 M leupeptin, 100 M pepstatin A, 17.5 M -glycerophos-
phate, and 2.5 M MG132). For pp65 immunoprecipitation, the cleared lysate
from each plate was split into two 1.8-ml tubes, and 800 l of monoclonal
anti-pp65 (clone 28-19) was added to each tube. Immunoprecipitation was car-
ried out at 4°C for 4 h. Protein G plus agarose (Santa Cruz) was first washed
extensively with PBS, then blocked with an unlabeled HFF NETN lysate (600 l
agarose slurry added to a NETN lysate from approximately 3 million cells
incubated for 1 h at 4°C), washed extensively, and finally added to the labeled
lysates for the last hour. Immunoprecipitates were washed with NETN buffer
containing 0.1% sodium dodecyl sulfate (SDS), boiled in reducing sample buffer,
and run out on an 8% SDS-polyacrylamide gel. Extraction of labeled protein,
tryptic digestion, and phosphopeptide separation were carried out essentially as
described by Schlaepfer and Hunter (23).
RESULTS
Roscovitine alters the localization of pp65 within infected
cells. Several virion proteins are phosphorylated, but the im-
portance of this modification for their incorporation into par-
ticles has not been extensively studied. As a first step in deter-
mining whether virion proteins were substrates for cdk activity,
we determined if there were changes in their localization upon
treatment of infected cells with roscovitine. The most signifi-
cant difference was the retention of pp65 within the nuclei of
drug-treated infected cells. During a normal infection, input
pp65 from the inoculum is rapidly transported to the nucleus
(24). The newly synthesized pp65 continues to localize to the
nucleus during early times and viral DNA replication. After
48 h p.i., pp65 moves into the cytoplasm and is barely detect-
able within the nucleus (18). The transport of pp65 out of the
nucleus marks a shift to the late phase of infection. In cells
treated with roscovitine beginning at 24 h p.i., the accumula-
tion of pp65 in the cytoplasm is markedly inhibited at 96 h p.i.
(Fig. 1A and B). Results using two different anti-pp65 antibod-
ies are shown. For Fig. 1A, cells were stained with monoclonal
antibody 28-19. As previously reported (18), pp65 was local-
ized in the cytoplasm and accumulated in the juxtanuclear
assembly compartment in control cells. In contrast, pp65 was
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predominantly localized in the nuclei of cells treated with
roscovitine from 24 h p.i. This trend was observed for several
experiments, and the percentage of cells showing nuclear lo-
calization of pp65 in the presence of the drug was high but
variable. Two experiments were quantified using monoclonal
antibody 28-19, and an average of 85% of cells treated with
roscovitine exhibited nuclear pp65.
Nuclear accumulation was also observed if addition of rosco-
vitine was delayed until 48 h p.i. (Fig. 1A). In this case, pp65
was detected in the nuclei of approximately 95% of cells in two
experiments. If roscovitine was washed out of the cultures at
48 h p.i., pp65 was localized in both the nucleus and the
cytoplasm, but its accumulation at the assembly compartment
lagged behind that observed in cells that were not treated with
the drug (Fig. 1A). Approximately 27% of cells in two exper-
iments contained some pp65 in the nucleus after the drug was
removed. These experiments demonstrated the reversibility of
cdk inhibition.
In Fig. 1B, we show the distribution of pp65 detected with
monoclonal antibody 65-8. In control cells, we observed pp65
in the cytoplasm in a diffuse pattern, with some accumulation
at the juxtanuclear assembly compartment. If roscovitine was
added at 24 h p.i., pp65 was detected in both the nucleus and
the cytoplasm. In addition to the diffuse nuclear staining, pp65
also appeared to accumulate along the periphery of the nu-
cleus. As with monoclonal antibody 28-19, we observed nuclear
accumulation of the protein in cells treated with the inhibitor
from 48 h p.i.
cdk inhibition with roscovitine alters the phosphorylation
pattern of pp65. Previous work demonstrated that pp65 was
phosphorylated (12, 16). Work from our laboratory showed
that cdk inhibition with roscovitine did not cause a significant
change in the steady-state levels of pp65 (21), but these exper-
iments did not address the phosphorylation state of the pro-
tein. In order to determine if pp65 was a substrate for the cdk
in infected cells, we generated phosphopeptide maps of pp65
immunoprecipitated from cells treated with DMSO or rosco-
vitine beginning at 24 h p.i. Cells were labeled with 32Pi at 66 h
p.i., at which time pp65 is accumulating in the cytoplasm in con-
trol cells. The protein was immunoprecipitated from the radiola-
beled cells and gel purified. The isolated protein was then di-
gested with trypsin, and the resulting peptides were resolved in
two dimensions. Approximately 10 spots were detected, suggest-
ing that pp65 is heavily phosphorylated (Fig. 2A and B). As
expected, the phosphorylation pattern in Fig. 2B was similar to
that reported by Roby and Gibson (16). We observed notable
differences in the map generated for pp65 derived from cells
treated with roscovitine, but we did not observe the complete
absence of a particular peptide. Instead, the intensities of two
peptides were reduced, and those of two other peptides in-
creased, in cells treated with roscovitine, suggesting that the
phosphorylation state of pp65 was altered by treatment with
the drug.
Mutation of cdk sites does not alter the localization of pp65.
Analysis of the pp65 protein using the NetPhos program (2)
revealed a number of potential phosphorylation sites for cel-
lular kinases within the sequence, including two potential cdk
sites at Thr66 and Thr555 (Fig. 3). The latter site falls within
the previously described bipartite NLS (24); thus, it seemed
possible that nuclear retention of pp65 in the presence of
FIG. 1. Treatment of HCMV-infected fibroblasts with roscovitine
results in nuclear retention of pp65 at late times during infection. Cells
were treated with 20 M roscovitine from 24 or 48 h p.i. and were fixed
at 96 h p.i. For experiments testing the reversibility of the drug, rosco-
vitine was added at 24 h p.i. and removed at 48 h p.i. as described in
Materials and Methods. Cells were stained with monoclonal antibody
(MAB) 28-19 (A) or 65-8 (B) against pp65. The nuclei were counter-
stained with Hoechst stain (blue), and the anti-pp65 antibody was
detected with a fluorescein isothiocyanate-conjugated secondary anti-
body (green). Original magnification, 400.
FIG. 2. The phosphorylation pattern of pp65 changes upon treat-
ment of cells with roscovitine from 24 h p.i. Infected cells were labeled
with 32Pi beginning at 66 h p.i. in the presence or absence of the drug.
The pp65 from labeled lysates was immunoprecipitated with monoclo-
nal antibody 28-19. The protein was isolated from SDS-polyacrylamide
gels and subjected to digestion and separation as described in Mate-
rials and Methods. (A) Peptides separated at a high pH; (B) peptides
separated at a low pH. Arrows indicate peptides whose intensities
decreased, and stars indicate peptides whose intensities increased, in
cells treated with roscovitine.
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roscovitine could be mediated by inhibition of phosphorylation
at this site. To test this possibility, we generated mutations at
Thr555 and Thr66 in the pp65 sequence. The amino acids were
changed to nonphosphorylatable alanine residues. Plasmids
encoding wild-type or mutant pp65 proteins fused to EGFP
were transfected into human fibroblasts, which were then
seeded onto coverslips. Cells were subsequently infected with
Towne at a high MOI and were fixed 72 to 96 h p.i. The
localization of the EGFP fusion proteins was observed by flu-
orescence microscopy. As shown in Fig. 3, neither the mutation
of Thr66 to alanine nor that of Thr555 affected the ability of
pp65 to target to the nucleus in cells transiently expressing the
protein. More than 99% of cells exhibited nuclear localization
of the pp65 constructs. When cells were infected with HCMV,
the wild-type and mutant fusion proteins displayed cytoplasmic
localization at late times (Fig. 3), although less than 50% of
transfected cells showed this phenotype. Expression of pp65
from the plasmids was driven from the CMV major IE pro-
moter, and upon infection, the high levels of expression led to
the formation of intranuclear aggregates of the protein. Only a
small percentage of infected cells, approximately 20 to 30%,
exhibited cytoplasmic localization of pp65 fusion proteins at
this time point.
Because EGFP forms a dimer, it was possible that complex
formation was affecting the localization of wild-type or mutant
pp65 in the assays described above. Moreover, it was also
possible that the wild-type pp65 expressed from the virus used
for superinfection formed complexes with the mutant pp65
proteins and altered their trafficking. To test these possibilities,
experiments similar to those described above were performed
with pp65 constructs lacking EGFP. In this case, the pp65-
negative Ad169 RV (25) was used for superinfection of cells
transfected with plasmids encoding wild-type or mutant pp65
proteins. At 96 h p.i., cells were fixed, and coverslips were
stained with monoclonal antibody 65-8 to visualize the local-
ization of pp65 (Fig. 4). The results obtained were similar to
those for the experiments using EGFP fusions. The mutation
of the consensus cdk phosphorylation site at Thr66 or Thr555
to alanine did not inhibit the ability of pp65 to localize to the
cytoplasm late in infection. Thus, phosphorylation at these
sites does not appear to play a role in the localization of pp65.
Accumulation of pp65 in the cytoplasm late in infection is
dependent on the Crm1 exporter. The biphasic distribution of
pp65 (first nuclear, then cytoplasmic) suggested that there
might be an alteration in the relative rates of nuclear import
and export of the protein at early and late phases of infection.
Given the change in the phosphorylation pattern of pp65
caused by cdk inhibition, it seemed possible that this could
alter the protein’s localization if the binding of targeting sig-
nals by transport receptors, such as importins and exportins,
was affected. The interactions between localization signals and
the receptors can be modulated by different mechanisms (for a
review, see reference 14). First, the signal can be obscured
from the receptor by intramolecular mechanisms such as pro-
tein folding, disulfide bonds, or phosphorylation. Second, the
interaction can be blocked by the binding of other molecules,
such as RNA or other proteins, to the cargo. Finally, modifi-
cation of the protein by phosphorylation can simply change the
affinity of the receptor for the signal. Since pp65 accumulated
in the nuclei of cells treated with a cdk inhibitor, it seemed
unlikely that the altered phosphorylation was affecting nuclear
import. In fact, the data were consistent with changes in the
ability of the protein to be exported. We therefore asked if
FIG. 3. Mutation of putative cdk sites in EGFP-pp65 does not alter
relocalization to the cytoplasm late in infection. (A) Sequences of
putative cdk sites in pp65. aa, amino acid. (B) Human fibroblasts were
transfected with plasmids encoding wild-type (wt) or mutant (T66A or
T555A) pp65 proteins fused to EGFP. Cells were either infected with
HCMV Towne at a high MOI or mock infected. Cells were fixed at
90 h p.i. Arrowheads indicate cells displaying cytoplasmic pp65 local-
ization. Original magnification, 400.
FIG. 4. Mutation of putative cdk sites in pp65 does not alter relocal-
ization to the cytoplasm in cells infected with the pp65-null virus RV.
Human fibroblasts were transfected with plasmids encoding wild-type
(WT) or mutant (T66A or T555A) pp65 proteins. Cells were either in-
fected with RV at a high MOI or mock infected. Cells were fixed at 96 h
p.i. and stained with monoclonal antibody 65-8 directed against pp65. The
nuclei were counterstained with Hoechst stain (blue), and the anti-pp65
antibody was detected with a fluorescein isothiocyanate-conjugated sec-
ondary antibody. Original magnification, 400.
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pp65 was a target for Crm1, the best-studied nuclear export
receptor.
In order to determine whether there might be a change in
the relative rates of nucleocytoplasmic transport at late times
in infection, we treated infected cells with LMB at 72 h p.i., a
time at which the majority of pp65 was localized in the cyto-
plasm. LMB inhibits the Crm1-dependent export of proteins
from the nucleus; thus, if the cytoplasmic localization of pp65
resulted from higher rates of Crm1-dependent export relative
to import, treatment with LMB would result in the accumula-
tion of pp65 in the nucleus. Incubations with LMB were car-
ried out with or without cycloheximide. After 1 and 3 h of
treatment with the export inhibitor, cells were fixed and stained
for pp65. Treatment of cells with LMB for 1 or 3 h resulted in
accumulation of pp65 in the nuclei of 95% of cells (Fig. 5).
The observation that pp65 accumulated in the nuclei of cells
treated with LMB and cycloheximide for merely 1 h had strong
implications. First, the data indicated that pp65 was not
static in the cell. Furthermore, the results suggested that
pp65 was capable of shuttling between the nucleus and the
cytoplasm. Interestingly, treatment of cells with cyclohexi-
mide alone resulted in a low level of nuclear accumulation
of pp65, but it was significantly lower than that observed
when LMB was added.
To determine if inhibition of cdk activity for short periods
affected pp65 localization like the disruption of Crm1-medi-
ated export, roscovitine was added at 72 h p.i. for only a 3-h
period. The effect of the cdk inhibitor on pp65 localization was
not as uniform as that of LMB. A mixed pattern of localization
was observed, and the percentage of cells showing nuclear
pp65 was low and variable between experiments (data not
shown). If, however, the cells were incubated with roscovitine
for 24 h (between 72 and 96 h p.i.), the effect on pp65 local-
ization was more striking; the protein was relocalized to the
nucleus in approximately 86% of the cells in two experiments
quantified with monoclonal antibody 28-19 (Fig. 6). These data
suggested that roscovitine did not have an immediate effect on
pp65 nuclear export like that observed with direct inhibition of
the Crm1 exporter but that prolonged incubation with the cdk
inhibitor did have a pronounced effect on export.
DISCUSSION
Our previous studies using the cdk inhibitor roscovitine have
shown that cdk activity is required at multiple stages during
HCMV infection. At the early phase of infection, cdk function
is required for proper processing of viral transcripts, for ex-
pression of early gene products, and for establishing an envi-
ronment suitable for viral DNA replication (20). At later times,
cdk activity appears to be required for virion maturation and
the release of infectious virus (3, 21). In this paper we have
extended these studies and demonstrate that cdk activity is also
important for the posttranslational modification and localiza-
tion of the abundant virion tegument protein pp65.
Treatment of infected cells with the cdk inhibitor roscovitine
led to accumulation of pp65 in the nucleus, even at late phases
of infection. In contrast, pp65 in control cells was distributed in
FIG. 5. The cytoplasmic accumulation of pp65 late in infection is reversed by LMB. HCMV-infected cells were treated with LMB or methanol
(MeOH) in the presence of cycloheximide (CHX) beginning at 72 h p.i. Cells were fixed at 73 or 75 h p.i. and stained with monoclonal antibody
65-8. The nuclei were counterstained with Hoechst stain (blue), and the anti-pp65 antibody was detected with a fluorescein isothiocyanate-
conjugated secondary antibody. Original magnification, 400.
FIG. 6. Late addition of roscovitine to infected cells causes the
nuclear accumulation of pp65. Roscovitine (20 M) was added at 72 h
p.i., a time when pp65 is predominantly localized in the cytoplasm.
Cells were fixed at 96 h p.i., and coverslips were stained with mono-
clonal antibody 28-19. The nuclei were counterstained with Hoechst
stain (blue), and the anti-pp65 antibody was detected with a fluores-
cein isothiocyanate-conjugated secondary antibody. Original magnifi-
cation, 400.
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the cytoplasm late in infection. Phosphopeptide mapping of
pp65 immunoprecipitated from infected cells treated with the
drug revealed that the phosphorylation pattern of the protein
was also changed when cdk activity was inhibited. Taken to-
gether, these observations suggested that pp65 was a substrate
for cdk in infected cells and that cdk-mediated phosphoryla-
tion controlled pp65 localization. However, mutational analy-
ses of potential cdk sites within the protein sequence did not
alter the ability of pp65 to be relocalized to the cytoplasm late
in infection, indicating that the two phenomena might not be
related. It is possible that both T66 and T555 must be mutated
within the same molecule in order to affect protein localization
in our assay. Alternatively, the effects on pp65 phosphorylation
could be indirect; that is, cdk could activate another kinase or
inhibit a phosphatase that acts on pp65. Determination of the
identity of pp65 phosphopeptides will allow us to define path-
ways by which roscovitine leads to altered pp65 localization. It
is possible that inhibition of cdk activity could affect the func-
tion of other proteins that regulate the trafficking of pp65.
The accumulation of pp65 in the nuclei of infected cells
treated with roscovitine prompted us to examine the mecha-
nisms underlying the biphasic localization of this protein dur-
ing infection. Our data indicate that the nuclear targeting of
pp65 is not affected by mutation of a potential phosphorylation
site within the bipartite localization signal, because the T555A
mutant was localized to the nucleus in transfected cells. In
addition, we found that a functional Crm1 exporter is required
for relocalization of pp65 to the cytoplasm late in infection.
Our strongest evidence that pp65 is a nucleocytoplasmic shut-
tling protein came from experiments where LMB and cyclo-
heximide were added to infected cell cultures at 72 h p.i., when
pp65 was cytoplasmic. After a 1-h incubation, pp65 had accu-
mulated in the nuclei of the majority of cells, suggesting that
pp65 was dynamic and retained the ability to be targeted to the
nucleus late in infection. Thus, it does not appear that pp65 is
retained in the cytoplasm in a static state late in infection.
Short incubations with the cdk inhibitor starting at 72 h p.i. did
not have the same impact on pp65 localization, but nuclear
accumulation of pp65 was observed after 24 h. The delayed
effect of roscovitine on pp65 localization compared to that of
LMB may reflect the reversibility of the cdk inhibitor as op-
posed to LMB.
Our preliminary data using glutathione S-transferase–Crm1
pulldown assays indicate that the interaction between pp65 and
Crm1 is not direct, but further studies are necessary in the
context of infection to characterize the nature of the interac-
tions. Our data do not exclude the possibility that roscovitine
inhibits the nuclear export system. However, based on our
observations that pp65 appears to shuttle within infected cells,
we have developed a model to explain the distribution of pp65
during infection. At early phases of infection, the rate of pp65
nuclear import is greater than the rate of export, and thus, the
protein is localized to the nucleus. After 48 h p.i., we believe
that there is a shift in the steady-state equilibrium that results
in cytoplasmic accumulation of pp65; that is, the rate of export
becomes greater than the rate of import. Although the ob-
served changes in the phosphorylation pattern of pp65 in the
presence of roscovitine support our model, phosphopeptide
mapping of pp65 at early and late phases of infection would
confirm our hypothesis that phosphorylation of pp65 mediates
this equilibrium shift. Therefore, additional experiments are
necessary to decipher the complex trafficking pathways of pp65
during infection.
In summary, we have described the nuclear accumulation of
pp65 within infected cells treated with the cdk inhibitor rosco-
vitine. We show that cdk activity is required even at very late
stages of infection for the proper posttranslational modifica-
tion and localization of virion proteins. These studies provide
the basis for future experiments designed to elucidate how the
virus utilizes multiple pathways to promote nuclear egress and
cytoplasmic assembly of the virion.
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